Motility Disorders Constipation
pain, American Pain Society Annual Meeting, Phoenix, 2001; abstract 790.
10. Sykes NP, An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer, Palliat Med, 1996;10:135–44.
11. Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, et al., Treatment of opioid-induced constipation with oral naloxone: a pilot study, Clin Pharmacol Ther, 1992;52:90–5.
12. Latasch L, Zimmermann M, Eberhardt B, et al., Treatment of morphine-induced constipation with oral naloxone, Anaesthesist, 1997;46:191–4.
13. Cheskin LJ, Chami TN, Johnson RE, et al., Assessment of nalmefene glucuronide as a selective gut opioid antagonist, Drug Alcohol Depend, 1995;39:151–4.
14. Yuan CS, Foss JF, Moss J, Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine, Eur J Pharmacol, 1995;276:107–11.
15. Yuan CS, Foss JF, O’Connor M, et al., Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial, Clin Pharmacol Ther, 1996;59:469–75.
16. Yuan CS, Foss JF, O’Connor M et al., Gut motility and transit changes in patients receiving long-term methadone maintenance, J Clin Pharmacol, 1998;38:931–5.
17. Yuan CS, Foss JF, O’Connor M, et al., Methylnaltrexone for reversal of constipation due to chronic methadone use, JAMA, 2000;283:367–72.
18. Yuan CS, Wei G, Foss JF, et al., Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-
controlled trial, J Pharmacol Exp Ther, 2002;300:118–23. 19. Portenoy RK, Thomas J, Moehl Boatwright ML, et al., Subcutaneous methylnaltrexone for the treatment of opioid- induced constipation in patients with advanced illness: A double-blind, randomized, parallel group, dose-ranging study, J Pain Symptom Manage, 2008;35:458–68.
20. Slatkin N, Thomas J, Lipman AG, et al., Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients, J Support Oncol, 2009;7:39–45.
21. Thomas J, Karver S, Cooner GA, et al., Methylnaltrexone for opioid-induced constipation in advanced illness, N Engl J Med, 2008;358:2332–43.
22. Thomas J, Wang W, Yan N, et al., Analysis of response to methylnaltrexone by response to previous dose in advanced illness patients with opioid-induced constipation, Proceedings of ASCO, 2008; abstract 9626.
23. Earnshaw SR, Klok RM, Iyer S, et al., Cost effectiveness of methylnaltrexone bromide, Aliment Pharmacol Ther, 2010;31(8):911–21.
24. Blonsky ER, Michna E, Schulman S, et al., Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic non-malignant pain. American Pain Society Annual Meeting, San Diego, CA, May 2009.
25. Viscuzi E, Rathmell J, Fichera A, et al., Methylnaltrexone in post-operative bowel dysfunction: Results of a double-blind, randomized, placebo-controlled trial in segmental colectomy patients. ASA Annual Meeting [abstract A-893], October, 2005, Atlanta, Georgia.
26. Anissian L, Vincent K, Jazayeri MJ, et al., Methylnaltrexone for opioid-induced constipation during rehabilitation
following orthopedic procedures: A double-blind, randomized clinical study, American Academy of Physical Medicine Annual Meeting [abstract 267], October 22–25, 2009, Austin, Texas.
27. Nassar AP Jr, Queiroz da Silva FM, de Cleva R, Constipation in intensive care unit, J Crit Care, 2009;24:630.e9–12.
28. van der Spoel JI, Oudemans-van Straaten HM, Kuiper MA, et al., Laxation of critically ill patients with lactulose or polyethylene glycol: A two-center randomized, double-blind, placebo-controlled trial, Crit Care Med, 2007;35:2726–31.
29. Woo M, O’Connor MF, Yuan C-S, Moss J, Reversal of opioid-induced gastric dysfunction in a critically ill burn patient after methylnaltrexone, Anesth Analg, 2008;107: 1965–7.
30. Ladanyi A, Temkin SM, Moss J, Subcutaneous methylnaltrexone to restore post-operative bowel function in a chronic opiate user, Int J Gynecologic Cancers, 2010;20: 308–10.
31. Sawh SB, Danga A, Selveraj IP, et al., Use of methylnaltrexone for the treatment of opioid-induced constipation in critical care patients, Critical Care, 2010;14(Suppl. 1):486.
32. Yuan CS, Foss JF, Gastric effects of methylnaltrexone on mu, kappa, and delta opioid agonists induced brainstem unitary responses, Neuropharmacology, 1999;38:425–32.
33. Yuan CS, Foss JF, Oral methylnaltrexone for opioid-induced constipation, JAMA, 2000;284:1383–4.
34. Progenics Pharmaceuticals, Inc., Progenics Pharmaceuticals Initiates Oral Methylnaltrexone Phase 3 Trial in Patients with Chronic Non-Cancer Pain, Press release, 2010. Available at:
www.progenics.com (accessed September 8, 2010).
42
US GASTROENTEROLOGY & HEPATOLOGY REVIEW
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100